NDA submission progress for ALXN1840 in Wilson disease sends Monopar Therapeutics stock up 7.61%

Traders Union
All News
Financial News
Monopar Therapeutics jumps 7.61% today

Highlights

Monopar Therapeutics advances toward NDA submission for ALXN1840 in Wilson disease, increasing regulatory approval and commercialization prospects.
Investor sentiment improves as the clinical development timeline for ALXN1840 raises expectations for MNPR's potential market entry.
Technicals show sustained bullish momentum and overbought signals, with expected price action between $79.70 and $96.28 in the next four days.

Commercialization prospects rise as ALXN1840 advances toward nda

Monopar Therapeutics continues to make progress towards a New Drug Application (NDA) submission for ALXN1840 as a treatment for Wilson disease, according to Rttnews. Advancing toward regulatory approval of ALXN1840 increases the likelihood of commercialization, drawing investor focus to the company's clinical development timeline. This development elevates expectations for potential market entry, fostering positive sentiment toward MNPR.

Overbought signals intensify as MNPR outpaces technical benchmarks

Technically, MNPR is trading well above the moving averages on multiple timeframes: MA-20 at $77.79 and MA-50 at $68.99 on the H1 chart, and MA-200 at $66.99 on the daily chart. The Ichimoku Kijun at $76.15 currently acts as immediate support. Most momentum indicators, including the Moving Average Convergence Divergence (MACD), Average Directional Index (ADX), Stochastic RSI, and Commodity Channel Index (CCI), remain on buy signals, while the Relative Strength Index (RSI) is elevated at 77.09, reflecting overbought conditions. Bull/Bear Power is also in an overbought state, indicating strong buyer dominance within the session, with only the Awesome Oscillator appearing neutral.

Upside breakout likely as price consolidates near volatility band

Over the next four trading days, the anticipated price range for MNPR is $79.7009 to $96.2791, marking a volatility band relative to current levels. There is a very high probability the price direction will be upward, while a sustained drop below immediate support at $76.15 is considered much less likely given prevailing indicators. The base case scenario is for price to consolidate within this corridor, with potential for an upside breakout if momentum persists and resistance is surpassed.

Viktoras Karapetjanc, expert at Traders Union, sees strong momentum and robust sentiment supporting Monopar Therapeutics. He notes that progress toward NDA submission for ALXN1840 is a major regulatory milestone, fueling optimism around future commercialization. Technicals reinforce the bullish view, with the price holding well above key support and most momentum indicators positive. Karapetjanc believes upside is favored if momentum persists. "With regulatory progress and positive signals, I expect MNPR to stay strong within its current range and possibly attempt a breakout if sentiment holds."

Earlier, analysts noted that Monopar Therapeutics was exhibiting strong bullish momentum amid elevated volatility and overbought signals. With the stock now advancing on both technical and regulatory catalysts, traders should monitor for signs of either continued upside acceleration or a potential shift in short-term momentum as MNPR approaches new highs.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.